评估DPP4抑制剂对TGF-β2诱导的透镜透明度的治疗效果
Niki Talebian1, Pei-Kang Liu2, Joanne Lee1
1Department of Ophthalmology, Louis J. Fox Center for Vision Restoration, University of Pittsburgh School of Medicine, Pittsburgh, PA 15219, USA.
Experimental eye research
|March 11, 2026
概括
像维尔达格利普丁这样的二乙酶-4 (DPP4) 抑制剂在白内障手术后预防后囊化 (PCO) 方面表现有前途. 这些药物可以通过向特定的信号通路来减少透镜细胞中的纤维变化.
科学领域:
- 眼科医生 眼科 眼科
- 细胞生物学 细胞生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 后囊化 (PCO) 是白内障手术后的一个常见并发症.
- PCO源自透镜上皮细胞 (LECs) 经历了上皮-介质细胞过渡 (EMT),影响视力.
- 目前用于PCO的治疗方法通常需要侵入性手术.
研究的目的:
- 为了研究二二酶-4 (DPP4) 抑制剂在防止LEC中TGF-β诱导的EMT的疗效.
- 探索西塔利普丁,萨萨利普丁和维尔达利普丁作为PCO治疗药物的潜力.
- 确定DPP4抑制剂是否可以减轻纤维化变化并减缓PCO进展.
主要方法:
- 在TGF-β2暴露之前,人类LEC和小鼠镜片被用DPP4抑制剂治疗.
- 分析了表皮-介质细胞过渡 (EMT) 标记物 (纤维素,维门丁,α-平滑肌肉动蛋白).
- 技术包括免疫染色,西部斑点和RT-qPCR来评估标记物表达和Smad2酸化.
主要成果:
- DPP4抑制剂有效地减弱了TGF-β2诱导的EMT标记物在细胞和透镜扩展培养物中.
- 抑制Smad2酸化被确定为作用机制.
- 维尔达格利普丁治疗显着减少了TGF-β2诱导的透镜不透明度在探索模型中.
结论:
- DPP4 抑制剂通过抑制TGF-β诱导的EMT,显示出预防PCO的潜力.
- 维尔达格利普丁作为PCO的非侵入性药理疗法特别有前途.
- 用DPP4抑制剂准TGF-β信号通路为PCO提供了一个新的治疗策略.
关键词:
这是一种DPP4抑制剂.萨克萨格利普丁是一种.西塔格利普丁是如何使用的维尔达格利普丁 (Vildagliptin) 是一个非常重要的药物.白内障是什么?白内障是什么?白内障是什么?表皮 - 介质细胞过渡.后部囊化变暗的情况更多相关视频
11:13Adenoviral Gene Therapy for Diabetic Keratopathy: Effects on Wound Healing and Stem Cell Marker Expression in Human Organ-cultured Corneas and Limbal Epithelial Cells
Published on: April 7, 2016
9.6K
05:51Characterization of a Novel Human Organotypic Retinal Culture Technique
Published on: June 9, 2021
4.8K
相关概念视频
Dipeptidyl Peptidase 4 Inhibitors
845
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
845
Glucagon-like Receptor Agonists
1.1K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.1K
TGF - β Signaling Pathway
10.8K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.8K
Open Angle Glaucoma: Treatment
1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
